Science is Boss | Bayer x Vividion
Автор: Bayer Global
Загружено: 2025-11-24
Просмотров: 190
Why do 90 percent of disease‑driving proteins remain out of reach for today’s medicines?
In this conversation, Bayer CEO Bill Anderson sits down with Aleksandra Rizo, CEO of Vividion Therapeutics, our arm's length company, to explore this and other questions like:
What makes small molecules so powerful for access and convenience, and how is Vividion flipping the script on proteins once considered “undruggable”?
What’s happening in research and the early clinical trials for patients facing squamous non‑small cell lung cancer and colorectal cancer, and could a new medicine reach patients by the end of this decade? 🎥🔬
Check out Bill and Aleksandra’s conversation, add your questions in the comments, and stay tuned for more stories from the front lines of discovery.
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
